PExA 過去の業績
過去 基準チェック /06
PExA's earnings have been declining at an average annual rate of -0.5%, while the Life Sciences industry saw earnings growing at 28.5% annually. Revenues have been growing at an average rate of 6.1% per year.
主要情報
-0.5%
収益成長率
25.7%
EPS成長率
Life Sciences 業界の成長 | 31.8% |
収益成長率 | 6.1% |
株主資本利益率 | -106.7% |
ネット・マージン | -668.1% |
次回の業績アップデート | 08 Nov 2024 |
最近の業績更新
Recent updates
収支内訳
PExA の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 1 | -9 | 9 | 0 |
31 Mar 24 | 2 | -8 | 9 | 0 |
31 Dec 23 | 2 | -8 | 9 | 0 |
30 Sep 23 | 4 | -6 | 9 | 0 |
30 Jun 23 | 6 | -4 | 9 | 0 |
31 Mar 23 | 6 | -4 | 9 | 0 |
31 Dec 22 | 6 | -4 | 9 | 0 |
30 Sep 22 | 4 | -5 | 9 | 0 |
30 Jun 22 | 2 | -8 | 8 | 0 |
31 Mar 22 | 2 | -7 | 8 | 0 |
31 Dec 21 | 2 | -8 | 8 | 0 |
30 Sep 21 | 2 | -9 | 8 | 0 |
30 Jun 21 | 2 | -8 | 8 | 0 |
31 Mar 21 | 1 | -8 | 7 | 0 |
31 Dec 20 | 1 | -8 | 7 | 0 |
30 Sep 20 | 1 | -8 | 8 | 0 |
30 Jun 20 | 1 | -8 | 8 | 0 |
31 Mar 20 | 1 | -9 | 8 | 0 |
31 Dec 19 | 4 | -6 | 8 | 0 |
30 Sep 19 | 5 | -5 | 8 | 0 |
30 Jun 19 | 5 | -4 | 7 | 0 |
31 Mar 19 | 5 | -4 | 7 | 0 |
31 Dec 18 | 3 | -6 | 7 | 0 |
30 Sep 18 | 2 | -6 | 6 | 0 |
30 Jun 18 | 2 | -5 | 6 | 0 |
31 Mar 18 | 2 | -6 | 5 | 0 |
31 Dec 17 | 2 | -5 | 5 | 0 |
30 Sep 17 | 3 | -6 | 7 | 0 |
30 Jun 17 | 4 | -4 | 7 | 0 |
31 Mar 17 | 4 | -4 | 7 | 0 |
31 Dec 16 | 4 | -3 | 8 | 0 |
30 Sep 16 | 4 | -3 | 4 | 0 |
30 Jun 16 | 3 | -4 | 3 | 0 |
31 Mar 16 | 3 | -3 | 2 | 0 |
31 Dec 15 | 3 | -3 | 1 | 0 |
30 Sep 15 | 1 | -1 | 0 | 0 |
30 Jun 15 | 1 | 0 | 0 | 0 |
31 Mar 15 | 0 | 0 | 0 | 0 |
31 Dec 14 | 0 | 0 | 0 | 0 |
質の高い収益: PEXA B is currently unprofitable.
利益率の向上: PEXA B is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: PEXA B is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year.
成長の加速: Unable to compare PEXA B's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: PEXA B is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (36%).
株主資本利益率
高いROE: PEXA B has a negative Return on Equity (-106.73%), as it is currently unprofitable.